#NWSCONF2023


MeMed’s Presentation Theater at
MeMed is transforming patient care by listening to the immune system and turning host response signals into clinical action.
Watch theater presentation


Dr. Eran Eden
Dr. Eran Eden is the Co-founder and CEO of MeMed since its inception in 2009. He lead MeMed from an idea to a rapidly growing company that is pioneering the field of host-response technologies.

Dr. Debra Goff
Dr. Goff is an Infectious Diseases Specialist pharmacist at The Ohio State University Wexner Medical Center and global antibiotic stewardship expert.
Is it a bacterial or viral infection? Using host-response technologies to decode the immune system and aid antibiotic stewardship
What would your practice look like if you had a 15-minute test that could differentiate between a bacterial and viral infection? MeMed BV® is the first rapid and accurate (blinded and external validation) host-response technology for distinguishing between bacterial and viral infections in under 15 minutes, and it is changing the paradigm in infectious disease patient management.

About MeMed
At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.
Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.


Contact us
Come join MeMed's Presentation Theater at IDWeek

Sheldon L. Kaplan, MD
Head, Pediatric Infectious Disease Section, Baylor College of Medicine
New Developments in Infectious Diseases Diagnostics:
112 - A Rapid Host-Protein Signature Based on TNF-related Apoptosis-Induced Ligand (TRAIL), Interferon Gamma Induced Protein-10 (IP-10) and C-Reactive Protein (CRP) Accurately Differentiates Between Bacterial and Viral Infection in Febrile Children: Apollo Sub-Study.

Alon Angel
International Investigator Award Product Associate, MeMed
COVID-19 Complications, Co-infections and Clinical Outcomes:
32 - Host Immune-Protein Signature Combining TRAIL, IP-10 and CRP for Early and Accurate Prediction of Severe COVID-19 Outcome